

# Mario Campone



**Member of the IHI JU Science & Innovation Panel**

**General Director  
Medical oncologist**

**Institut de Cancérologie de l'Ouest  
Nantes – Angers, France**

Professor Mario Campone is the CEO of Institut de Cancérologie de l'Ouest (ICO). He holds a doctoral degree as Medical Doctor with a Certificate in Oncology since 1998 and a Physician Doctor in Life and Health Sciences since 2010. His training was held in the University of Nantes, as well as at Beatson Institute in Glasgow (UK).

Currently he is handling several functions. He is hospital practitioner specialist of Medical Oncology at ICO. He is also a Professor of Medical Oncology at the University of Angers. He is responsible for the Phase I unit labeled by French National Cancer Institute (CLIP2), and the Head of Breast cancer and translational research of ICO, thus interacting directly with the platforms of transcriptomics and proteomics as well as the bioinformatic Unit of ICO.

He is a member of several international and European organizations including ASCO, EORTC, and ESMO.

At national level, he is deputy head of Iliad SIRIC (Integrated cancer research sites) since 2018, deputy president of Unicancer (Union of French Comprehensive Cancer Center) since 2019 and deputy head of the Pays de la Loire Health Observatory since 2022. He was previously Chairman of the Early Study Group (2011-2016) and vice-chairman of the Personalized Medicine Group (2015-2019) of Unicancer. Prof. Campone is a founding member of a biotech, ONCOTHEREX, who develop an innovative technology to test new treatments on cancer tissues.

Prof. Campone is part of the Center for Cancer Research and immunology Nantes-Angers UMR-1307/CNRS UMR 6075 Inserm, led by Dr. Juin where studies focus on identifying how aberrant survival contributes to tumor escape, and that promote resistance to conventional and targeted therapies, and on identifying novel targets for innovative treatments. He created ORPHEO with the National Veterinary School of Nantes, a multi-disciplinary group working on the prognostic factors in breast cancer as well as factors predictive of response to targeted therapies.

Prof. Campone is highly experienced in clinical research as the coordinator of 26 studies since 2003 and as a principal Investigator in numerous clinical studies of new agent therapeutic in breast pathology (81 studies). He is an author or co-author of more than 354 publications (H index 70) in peer reviewed journals, in the field of cancer and molecular biology.

Beyond oncology, Prof. Campone has acquired a long experience in personalized medicine, translational science, bio-informatic. He has a global view on scientific challenges and is able to interact with its scientific and innovation networks to develop his vision.